New pill shows promise for nail psoriasis in first human test
NCT ID NCT05124080
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase study tested deucravacitinib, an oral drug, for treating nail psoriasis. The goal was to see if it improves nail appearance and symptoms. Only one person took part, and researchers measured changes in nail psoriasis severity over 48 weeks. Because it's so small, the results are just a first step.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Deucravacitinib
- What this could lead to
- If this works, it could point toward a new oral treatment for nail psoriasis, a condition that can be hard to treat.
- What could go wrong
- This is a very early, tiny study with only one participant, so results are not reliable. Larger trials are needed to know if it really helps.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NAIL PSORIASIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of Alabama at Birmingham - Department of Dermatology
Birmingham, Alabama, 35233, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a single cream tackle both skin and nail psoriasis?
- Can a urea cream beat vaseline for nail psoriasis?
- Can a daily patch fix your toenails? new trial aims to find out
- Could a nail polish treat psoriasis? small trial tests tofacitinib lacquer
- Nail psoriasis injection study halted after just one person